Q. Could you tell us a little about the PACIFIC trial in stage III nonsmall cell lung cancer (NSCLC)?
The PACIFIC trial evaluated the role of durvalumab, a programmed death-ligand 1 (PD-L1) antibody, in patients with locally advanced, surgically unresectable stage III NSCLC. 1 Following completion of chemotherapy and radiation, patients were randomized to receive one year of durvalumab or 
Q. What challenges remain in the use of immunotherapy in stage III NSCLC?
Work on biomarker discovery to select patients is an important priority. As the next step, combination approaches that build on the benefits of durvalumab are already under development. This also opens the possibility to study immune checkpoint inhibition concurrently with radiotherapy for patients with locally advanced NSCLC.
Q. What is the potential of third-generation epidermal growth factor receptor (EGFR) inhibitors in the first-line treatment of metastatic EGFR-mutation-positive NSCLC?
Osimertinib has now emerged as a standard first-line therapy option for patients with EGFR exon 19 or 21 mutation. This recommendation is based on the results of the FLAURA study that demonstrated superior PFS for osimertinib over gefitinib/erlotinib with an impressive hazard ratio of 0.46. 2 The median PFS for patients treated with osimertinib as first-line therapy was 18.9 months, setting a new benchmark in this setting. In addition, superior activity in patients with brain metastases, favorable survival trend, and improved safety profile were all observed. 
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